Matches in SemOpenAlex for { <https://semopenalex.org/work/W3180545987> ?p ?o ?g. }
- W3180545987 abstract "Chronic myeloid leukemia (CML) represents 15% of newly diagnosed leukemia cases. In the United States, about 9000 new CML cases are diagnosed annually [1]. BCR-ABL1-targeted tyrosine kinase inhibitors (TKIs) have vastly changed the treatment and prognosis of CML. Before the introduction of TKIs, allogeneic hematopoietic stem cell transplantation (SCT) was the only known cure for CML. However, due to the advanced age of most patients with CML, this treatment modality was utilized in a small proportion of patients and mortality remained high. The TKIs have transformed CML into a manageable chronic disease state and have decreased the annual mortality to less than 2%. Thus, the prevalence of CML will continue to increase annually until the annual incidence equals the annual mortality, with an estimated potential plateau prevalence of 300,000–500,000 cases in the United States. There are currently five approved TKIs in the United States and in Europe. These include imatinib, dasatinib, nilotinib, bosutinib, and ponatinib. While imatinib changed the landscape of CML treatment drastically, the low rates of molecular response in addition to the high rates of discontinuation due to adverse effects led to the development of second- and third-generation TKIs. These TKIs are more potent than imatinib, have unique adverse effect profiles, and have activity against different molecular mutations, all of which must be considered when choosing a therapeutic agent. This chapter discusses the second- and third-generation TKIs and their role in CML therapy." @default.
- W3180545987 created "2021-07-19" @default.
- W3180545987 creator A5015140142 @default.
- W3180545987 creator A5025740487 @default.
- W3180545987 creator A5049385583 @default.
- W3180545987 creator A5090435894 @default.
- W3180545987 date "2021-01-01" @default.
- W3180545987 modified "2023-10-17" @default.
- W3180545987 title "CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors" @default.
- W3180545987 cites W1565948695 @default.
- W3180545987 cites W1814874339 @default.
- W3180545987 cites W1965429870 @default.
- W3180545987 cites W1970962784 @default.
- W3180545987 cites W1987060661 @default.
- W3180545987 cites W1990020715 @default.
- W3180545987 cites W1994309500 @default.
- W3180545987 cites W2009972868 @default.
- W3180545987 cites W2012238745 @default.
- W3180545987 cites W2035278640 @default.
- W3180545987 cites W2039531591 @default.
- W3180545987 cites W2051728915 @default.
- W3180545987 cites W2052923507 @default.
- W3180545987 cites W2054251966 @default.
- W3180545987 cites W2057718276 @default.
- W3180545987 cites W2057796192 @default.
- W3180545987 cites W2060882055 @default.
- W3180545987 cites W2068977368 @default.
- W3180545987 cites W2070568211 @default.
- W3180545987 cites W2076720738 @default.
- W3180545987 cites W2080125373 @default.
- W3180545987 cites W2085342571 @default.
- W3180545987 cites W2092606584 @default.
- W3180545987 cites W2097799776 @default.
- W3180545987 cites W2097946794 @default.
- W3180545987 cites W2101635775 @default.
- W3180545987 cites W2105783133 @default.
- W3180545987 cites W2106266094 @default.
- W3180545987 cites W2106392592 @default.
- W3180545987 cites W2107268345 @default.
- W3180545987 cites W2108470021 @default.
- W3180545987 cites W2115626434 @default.
- W3180545987 cites W2116153687 @default.
- W3180545987 cites W2117356576 @default.
- W3180545987 cites W2117806883 @default.
- W3180545987 cites W2124097332 @default.
- W3180545987 cites W2124196948 @default.
- W3180545987 cites W2128738046 @default.
- W3180545987 cites W2134566943 @default.
- W3180545987 cites W2143939343 @default.
- W3180545987 cites W2147109509 @default.
- W3180545987 cites W2152713204 @default.
- W3180545987 cites W2156145496 @default.
- W3180545987 cites W2157743993 @default.
- W3180545987 cites W2260921597 @default.
- W3180545987 cites W2281742031 @default.
- W3180545987 cites W2339943063 @default.
- W3180545987 cites W2397234997 @default.
- W3180545987 cites W2406641958 @default.
- W3180545987 cites W2467870347 @default.
- W3180545987 cites W2516246505 @default.
- W3180545987 cites W2516537857 @default.
- W3180545987 cites W2560342075 @default.
- W3180545987 cites W2587781815 @default.
- W3180545987 cites W2590307110 @default.
- W3180545987 cites W2592060299 @default.
- W3180545987 cites W2604610401 @default.
- W3180545987 cites W2612143330 @default.
- W3180545987 cites W2750206713 @default.
- W3180545987 cites W2751650152 @default.
- W3180545987 cites W2763572665 @default.
- W3180545987 cites W2766187515 @default.
- W3180545987 cites W2790692615 @default.
- W3180545987 cites W2792113531 @default.
- W3180545987 cites W2793387867 @default.
- W3180545987 cites W2802371729 @default.
- W3180545987 cites W2887979887 @default.
- W3180545987 cites W2900595359 @default.
- W3180545987 cites W2909903492 @default.
- W3180545987 cites W2939870032 @default.
- W3180545987 cites W2972586553 @default.
- W3180545987 cites W2974825249 @default.
- W3180545987 cites W2977193627 @default.
- W3180545987 cites W2985268897 @default.
- W3180545987 cites W2991803470 @default.
- W3180545987 cites W2993191462 @default.
- W3180545987 cites W2994916398 @default.
- W3180545987 cites W3004158545 @default.
- W3180545987 cites W3009751715 @default.
- W3180545987 cites W3014612640 @default.
- W3180545987 cites W3014892303 @default.
- W3180545987 cites W3029545901 @default.
- W3180545987 doi "https://doi.org/10.1007/978-3-030-71913-5_5" @default.
- W3180545987 hasPublicationYear "2021" @default.
- W3180545987 type Work @default.
- W3180545987 sameAs 3180545987 @default.
- W3180545987 citedByCount "0" @default.
- W3180545987 crossrefType "book-chapter" @default.
- W3180545987 hasAuthorship W3180545987A5015140142 @default.
- W3180545987 hasAuthorship W3180545987A5025740487 @default.
- W3180545987 hasAuthorship W3180545987A5049385583 @default.